Plain-English translation of NCT07238868 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a long-term follow-up study for people who completed an earlier trial of , a new medication being developed to treat focal epilepsy. The study will track how safe and effective this medication is when you take it daily at increasing doses for up to two years. Researchers will also monitor how your body processes the medication and how well it controls your seizures.
Early testing showed promise for this medication, but researchers need to understand how it performs and whether it remains safe when people take it for much longer periods. This extended study will help determine if this treatment is truly beneficial for long-term epilepsy management.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will start by taking the medication at a lower dose (10 mg once daily) for two weeks. If you tolerate it well, your dose will increase to 20 mg once daily, which you'll continue for up to two years. You'll have regular study visits to check how you're doing, discuss any side effects, and have blood work done to measure how your body is handling the medication. You'll also continue tracking your seizures in a daily diary.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
Australia
Phase
Testing effectiveness
Sponsor
Shanghai Zhimeng Biopharma, Inc.
Enrollment target
~144 participants
Started
August 2025
Primary completion
January 2029
Age range
18 Years – 70 Years
Last updated on clinicaltrials.gov in November 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Terence O'Brien, professor
Shanghai Zhimeng Biopharma, Inc.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.